ERYTECH Pharma develops ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs.
Its first product reported positive Phase III results of its pivotal study in Acute Lymphoblastic Leukemia (ALL) in Europe and is in four other clinical programs : a Phase IIb study in Acute Myeloid Leukemia (AML) , a Phase II study in pancreatic cancer and an Expanded Access program in ALL in Europe, and a Phase I/II study in ALL in the USA.
ERYTECH proprietary technology is based on encapsulation of therapeutic compounds into red blood cells.
The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, one with Orphan Europe (Recordati) and one with Teva.
ERYTECH Pharma provides a business update and reports its financial results for the six-month period ending June 30, 2015
ERYTECH Pharma announces the issuance of a new patent in the United States
ERYTECH Pharma announces today the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ERY-ASP (Invented Name: GRASPA®) for the treatment of patients with acute lymphoblastic leukemia (ALL).
ERYTECH Pharma announces the appointment of Eric Soyer as Chief Financial and Chief Operating Officer (CFO/COO).
WEBCAST – ERYTECH Pharma will announce its half-year results for 2015 on Monday September 28, 2015, after market close, and hold a presentation webcast on the September 29, 2015 at 2:30 pm CET / 8:30 am EDT.
ERYTECH Pharma attends BIO 2015 in Philadelphia, PA, USA from June 15 to 18, 2015.
ERYTECH Pharma participates and presents at EHA 20th Congress which takes place from June 11 to 14, 2015 in Vienna, Austria.
ERYTECH PHARMA attends and presents at Jefferies 2015 Healthcare Conference from June 1 to 4, 2015 in New-York, NY, USA